Research progress of urine TIMP-2×IGFBP-7 in early diagnosis, risk stratification and prognosis of acute kidney injury
10.3760/cma.j.cn114452-20210402-00212
- VernacularTitle:尿金属蛋白酶组织抑制剂-2与胰岛素样生长因子结合蛋白-7乘积在急性肾损伤的早期诊断、危险分层和预后评估中的研究进展
- Author:
Qian ZHANG
1
;
Yang ZHAO
;
Liyan CUI
Author Information
1. 北京大学第三医院检验科，北京100191
- Keywords:
Acute kidney injury;
Biomarkers;
Tissue inhibitor of metalloproteinases-2;
Insulin-like growth factor-binding protein-7
- From:
Chinese Journal of Laboratory Medicine
2021;44(10):964-969
- CountryChina
- Language:Chinese
-
Abstract:
Acute kidney injury (AKI) is a common complication in critically ill patients with complex etiology and high morbidity, which is closely related to the patient's mortality rate, hospital stay and long-term poor outcomes. Therefore, timely detection of AKI in the early reversible stage is particularly important to prevent its progression to renal failure and initiating renal replacement therapy. Therefore, exploring the relevant biomarkers in the occurrence and development of acute kidney injury has important clinical significance for the diagnosis and treatment of the disease. Tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor-binding protein-7 (IGFBP-7) are used as cell cycle arrest proteins, which has shown certain advantages in the early diagnosis, risk stratification, prognosis judgment, and treatment effect of acute kidney injury. Cell cycle arrest protein [TIMP-2]×[IGFBP-7] plays a role in acute kidney injury caused by various reasons and can be used as a reference index for disease prognosis.
